Sandbox ID Cardiovascular: Difference between revisions

Jump to navigation Jump to search
Line 65: Line 65:
===Rheumatic fever, secondary  prophylaxis===
===Rheumatic fever, secondary  prophylaxis===
:* Preferred regimen: [[Penicillin G benzathine]] 1.2 million units IM every 4 wk {{or}} [[Penicillin V potassium]] 250 mg orally BID {{or}} [[Sulfadiazine]] 1 g orally once daily {{or}} [[Macrolide]] or [[Azalide]] antibiotic (for patients allergic to [[Penicillin]] and [[Sulfadiazine]]) varied dose.
:* Preferred regimen: [[Penicillin G benzathine]] 1.2 million units IM every 4 wk {{or}} [[Penicillin V potassium]] 250 mg orally BID {{or}} [[Sulfadiazine]] 1 g orally once daily {{or}} [[Macrolide]] or [[Azalide]] antibiotic (for patients allergic to [[Penicillin]] and [[Sulfadiazine]]) varied dose.
:* Note: Duration of secondary prophylaxis for [[rheumatic fever]] differs for different scenarios. For [[Rheumatic fever]] with [[carditis]] and residual heart disease (persistent [[VHD]]) 10 y or until patient is 40 y of age (whichever is longer). For [[Rheumatic fever]] with [[carditis]] but no residual [[heart]] disease ([[no valvular disease]]) 10 y or until patient is 21 y of age (whichever is longer). For [[Rheumatic fever]] without [[carditis]] 5 y or until patient is 21 y of age (whichever is longer).
:* Note: Duration of secondary prophylaxis for [[rheumatic fever]] differs for different scenarios. For [[Rheumatic fever]] with [[carditis]] and residual heart disease (persistent [[VHD]]) 10 y or until patient is 40 y of age (whichever is longer). For [[Rheumatic fever]] with [[carditis]] but no residual [[heart]] disease ([[no valvular disease]]) 10 y or until patient is 21 y of age (whichever is longer). For [[Rheumatic fever]] without [[carditis]] 5 y or until patient is 21 y of age (whichever is longer).<ref name="pmid24603191">{{cite journal| author=Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton RA et al.| title=2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. | journal=J Am Coll Cardiol | year= 2014 | volume= 63 | issue= 22 | pages= e57-185 | pmid=24603191 | doi=10.1016/j.jacc.2014.02.536 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24603191  }} </ref>
----
----



Revision as of 16:04, 4 June 2015

Aortitis, infectious


Cardiovascular implantable electronic device infections


Endocarditis, prophylaxis


Intravascular catheter-related infections


Mediastinitis, acute


Myocarditis, viral


Pericarditis, fungal

  • Fungal Pericarditis[1]
Note: Corticosteroids and NSAIDs can support the treatment with antifungal drugs. Pericardiocentesis or surgical treatment is indicated for haemodynamic impairment. Pericardiectomy is indicated in fungal constrictive pericarditis.
Note: Corticosteroids and NSAIDs can support the treatment with antifungal drugs. Pericardiocentesis or surgical treatment is indicated for haemodynamic impairment. Pericardiectomy is indicated in fungal constrictive pericarditis.
  • Preferred regimen: Combination of three antibiotics including Penicillin.
Note: Corticosteroids and NSAIDs can support the treatment with antifungal drugs. Pericardiocentesis or surgical treatment is indicated for haemodynamic impairment. Pericardiectomy is indicated in fungal constrictive pericarditis.

Pericarditis, tuberculous

Note: Intrapericardial drainage is done if needed. If constriction develops inspite of medical therapy, pericardiectomy is indicated[1].

Pericarditis, viral

  • Viral pericarditis[1]
  • CMV pericarditis
  • Preferred regimen: immunoglobulin 1 time per day 4 ml/kg on day 0, 4, and 8; 2 ml/kg on day 12 and 16.
Note: Symptomatic treatment is given to the patients with viral pericarditis while in large effusions and cardiac tamponade pericardiocentesis is necessary. The use of corticosteroid therapy is contraindicated except in patients with secondary tuberculous pericarditis, as an adjunct to tuberculosis treatment. Drainage, if needed is done.
  • Coxsackie B pericarditis
  • Preferred regimen: Interferon alpha or beta 2,5 Mio. IU/m2 surface area s.c. 3×per week.
Note: Symptomatic treatment is given to the patients with viral pericarditis while in large effusions and cardiac tamponade pericardiocentesis is necessary. The use of corticosteroid therapy is contraindicated except in patients with secondary tuberculous pericarditis, as an adjunct to tuberculosis treatment. Drainage, if needed is done.
  • Adenovirus and parvovirus B19 perimyocarditis
  • Preferred regimen: Immunoglobulin 10 g intravenously at day 1 and 3 for 6–8 hours
Note: Symptomatic treatment is given to the patients with viral pericarditis while in large effusions and cardiac tamponade pericardiocentesis is necessary. The use of corticosteroid therapy is contraindicated except in patients with secondary tuberculous pericarditis, as an adjunct to tuberculosis treatment. Drainage, if needed is done.

Rheumatic fever, primary prophylaxis


Rheumatic fever, secondary prophylaxis


Septic pelvic vein thrombophlebitis

  • Right ovarian vein thrombosis
Note: Repeat CT scan after 3 months. If negative, stop anticoagulation. If still positive for thrombi, anticoagulate for 3 additional months.
  • Pelvic branch vein thrombosis
  • Negative for pelvic thrombi

References

  1. 1.0 1.1 1.2 Maisch B, Seferović PM, Ristić AD, Erbel R, Rienmüller R, Adler Y; et al. (2004). "Guidelines on the diagnosis and management of pericardial diseases executive summary; The Task force on the diagnosis and management of pericardial diseases of the European society of cardiology". Eur Heart J. 25 (7): 587–610. doi:10.1016/j.ehj.2004.02.002. PMID 15120056.
  2. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN; et al. (2003). "American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis". Am J Respir Crit Care Med. 167 (4): 603–62. doi:10.1164/rccm.167.4.603. PMID 12588714.
  3. Gerber MA, Baltimore RS, Eaton CB, Gewitz M, Rowley AH, Shulman ST; et al. (2009). "Prevention of rheumatic fever and diagnosis and treatment of acute Streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics". Circulation. 119 (11): 1541–51. doi:10.1161/CIRCULATIONAHA.109.191959. PMID 19246689.
  4. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton RA; et al. (2014). "2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines". J Am Coll Cardiol. 63 (22): e57–185. doi:10.1016/j.jacc.2014.02.536. PMID 24603191.
  5. Javier Garcia, Ramzi Aboujaoude, Joseph Apuzzio & Jesus R. Alvarez (2006). "Septic pelvic thrombophlebitis: diagnosis and management". Infectious diseases in obstetrics and gynecology. 2006: 15614. doi:10.1155/IDOG/2006/15614. PMID 17485796.